A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
Linda R DuskaVirginia L FiliaciJoan L WalkerLaura L HolmanEmily K HillRichard G MooreKari L RingMichael L PearlCarolyn Y MullerChristina L KushnirHeather A LankesMegan I SamuelsonKelley S CarrickAnand RajanWilliam H RodgersElise C KohnRichard L PiekarzKimberly K LesliePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This surgical window trial rapidly accrued in a multisite setting and evaluated PR as its primary endpoint and Ki-67 as secondary endpoint. Despite no immediate effect of entinostat on PR in this short-term study, lessons learned can inform future window and treatment trials.